The estimated Net Worth of Gary B. Gordon is at least $556 Tisíc dollars as of 24 February 2021. Dr Gordon owns over 3,000 units of Ayala Pharmaceuticals stock worth over $5,760 and over the last 4 years he sold AYLA stock worth over $0. In addition, he makes $550,311 as Chief Medical Officer at Ayala Pharmaceuticals.
Dr has made over 2 trades of the Ayala Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of AYLA stock worth $15,480 on 24 February 2021.
The largest trade he's ever made was exercising 3,000 units of Ayala Pharmaceuticals stock on 24 February 2021 worth over $15,480. On average, Dr trades about 1,000 units every 6 days since 2021. As of 24 February 2021 he still owns at least 11,520 units of Ayala Pharmaceuticals stock.
You can see the complete history of Dr Gordon stock trades at the bottom of the page.
Dr. Gary B. Gordon M.D., Ph.D. is the Chief Medical Officer at Ayala Pharmaceuticals.
As the Chief Medical Officer of Ayala Pharmaceuticals, the total compensation of Dr D at Ayala Pharmaceuticals is $550,311. There are 2 executives at Ayala Pharmaceuticals getting paid more, with Yossi Maimon CPA, M.B.A., CPA, MBA having the highest compensation of $692,182.
Dr D is 68, he's been the Chief Medical Officer of Ayala Pharmaceuticals since . There are no older and 4 younger executives at Ayala Pharmaceuticals.
Over the last 5 years, insiders at Ayala Pharmaceuticals have traded over $930,844 worth of Ayala Pharmaceuticals stock and bought 1,575,250 units worth $23,628,700 . The most active insiders traders include Growth Fund Limited Partner..., Murray A Goldberg a Growth Fund Limited Partner.... On average, Ayala Pharmaceuticals executives and independent directors trade stock every 37 days with the average trade being worth of $102,203. The most recent stock trade was executed by Gary B. Gordon on 24 February 2021, trading 3,000 units of AYLA stock currently worth $15,480.
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Ayala Pharmaceuticals executives and other stock owners filed with the SEC include: